Enzalutamide (MDV3100)

For research use only.

Catalog No.S1250

383 publications

Enzalutamide (MDV3100) Chemical Structure

CAS No. 915087-33-1

Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.

Selleck's Enzalutamide (MDV3100) has been cited by 383 publications

Purity & Quality Control

Choose Selective Androgen Receptor Inhibitors

Biological Activity

Description Enzalutamide (MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells. Enzalutamide is shown to increase autophagy.
Targets
Androgen Receptor [1]
(LNCaP cells)
36 nM
In vitro

Enzalutamide has greater affinity to AR than Bicalutamide does in a competition assay with 16β-[18F]fluoro-5α-DHT (18-FDHT) in castration-resistant LNCaP/AR cells (AR-overexpressing). While Enzalutamide shows no agonism in LNCaP/AR prostate cells. Enzalutamide antagonizes induction of prostate-specific antigen (PSA) and transmembrane serine protease 2 (TMPRSS2), combination with the synthetic androgen R1881 in parental LNCaP cells. Enzalutamide could inhibit the transcriptional activity of a mutant AR protein (W741C, mutation of Trp741 to Cys). [1] Enzalutamide also prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LNCAP MmexR5l1d3SxeHnjJGF{e2G7 MnTBO{Bl[Xm| NWG4[XB{QTVnIFX0U2g> NUHOT2ZlUUN3ME21MlEzKM7:TR?= Ml7CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
human LNCAP NGXoZmhHfW6ldHnvckBCe3OjeR?= NFzaNnkyKM7:TR?= NGPIT|JFVVOR MnP5TY5pcWKrdIOgdJJwe3SjdHWgd5Bm[2moaXOgZY51cWenbjDz[YNz\XSrb36gbY4hcHWvYX6gUG5ESVBiY3XscJMh\XiycnXzd4lv\yCjbnTyc4dmdiC{ZXPldJRweiCjdDCxNFAuOTByMH7N MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJzOEexO{c,OjB{MUi3NVc9N2F-
VCaP MkfsSpVv[3Srb36gRZN{[Xl? NIfBd|gyOCEQvF2= MYeyOEBp NIrqTodFVVOR NYfuNI9yW3WycILld5NmeyCuaXfhcoQudWWmaXH0[YQhSVJvRlygd4lodmGuaX7n MmnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5MUC0N|YoRjJ{N{GwOFM3RC:jPh?=
BCK4 NH74WmZHfW6ldHnvckBCe3OjeR?= NEfEN4YyOCEQvF2= M3nyb|ch\GG7cx?= NVTzZ4NpTE2VTx?= M{\UO2lvcGmkaYTzJIV{fHKjZHnvcE1u\WSrYYTl[EBxem:uaX\ldoF1cW:w M3HqZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEWxNVA6Lz5{NES1NVExQTxxYU6=
MCF7s NUnwR2hZTnWwY4Tpc44hSXO|YYm= NG\iVIMyOCEQvF2= M3jsOlYh\GG7cx?= NVP0bFR2TE2VTx?= Mo\uTY5pcWKrdIOg[ZN1emGmaX;sMY1m\GmjdHXkJJBzd2yrZnXyZZRqd25? NULMPJRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0OVEyODlpPkK0OFUyOTB7PD;hQi=>
PC-3 NV3JUGJMTnWwY4Tpc44hSXO|YYm= M4D5ZVExKM7:TR?= M4frflczKGh? MkfDSG1UVw>? M4Dz[WRw\XNibn;0JIlvcGmkaYSgZ4VtdCCycn;sbYZmemG2aX;u Mn3TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV|NES4OlQoRjJ3M{S0PFY1RC:jPh?=
CWR22Rv1 NGHwNWpHfW6ldHnvckBCe3OjeR?= MXmxOUDPxE1? M3LjZlI1KGh? MYDEUXNQ M1j1OGRw\XNibn;0JIFn\mWldDD0bIUh\nWubDDs[Y5ofGhiQWKg[ZhxemW|c3nvci=> MmPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
LNCAP/AR NHfnUnFCdnSjZ3;ubZN1KGGldHn2bZR6KGG|c3H5 NG[2OHZKSzVyIE2gNE4xOjFizszN MmP6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5MUe1OFQoRjJ5N{G3OVQ1RC:jPh?=
MDA-MB-453 M17ZTWFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= NWHqO3RUTUN3MDC9JFAvODR7IN88US=> NHTqTXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{exN|U3Pyd-MkO3NVM2Pjd:L3G+
LNCAP Mn2xRY51[WexbnnzeEBi[3Srdnn0fUBie3OjeR?= Mn7CO|IhcA>? MXPJR|UxKD1iMD6wOUDPxE1? MnPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzOUOyNVUoRjNyMUmzNlE2RC:jPh?=
LNCAP NUGwZ2pJSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> NGfkTm04OiCq NX\ZSIp2UUN3MDC9JFAvODlizszN MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF7M{KxOUc,OzBzOUOyNVU9N2F-
LNCAP NUCyT5NKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MkXIS2k2OCB;IECuNVIh|ryP MlnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyMUGyNVkoRjJ6MEGxNlE6RC:jPh?=
LNCAP NWi2SIZHSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MkXuN{Bl[Xm| MlvBTWM2OCB;IECuNVI4OSEQvF2= M4PQR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MES2N|E{Lz5{NkC0OlMyOzxxYU6=
LNCAP NVfJOVhZSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> NVzGc|NuPiCmYYnz NGDvUXBIUTVyIE2gNE4zQSEQvF2= M{j2c|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEGxNlE6Lz5{OECxNVIyQTxxYU6=
UAS-bla GripTite 293 NXnFVWZHSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> MV:xOkB1dyB{NDDo MXnJR|UxKD1iMD6zOlEh|ryP M12wU|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{CxN|Y5Lz5{N{OwNVM3QDxxYU6=
mammalian expression system M4XYNmFvfGGpb37pd5Qh[WO2aY\peJkh[XO|YYm= M4LiOVIzKHSxIEK0JIg> MonkSWM2OCB;IECuOFIh|ryP M4rNXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{i1OVA{Lz5{OEO4OVUxOzxxYU6=
VCaP M13xfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MX[xOFQhcA>? M3v5PGdKPTBiPTCwMlYyKM7:TR?= M1Ty[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKxOVg3Lz5{NUGyNVU5PjxxYU6=
LNCaP NXrL[lFKSW62YXfvcol{fCCjY4Tpeol1gSCjc4PhfS=> M1vKXFIhcA>? MX;FR|UxKD1iMD65NVUh|ryP Mn;uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5MUO1OlcoRjJ|N{GzOVY4RC:jPh?=
COS7 MUHBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NYXJfpVKOjRiaB?= M2LoOWlEPTBiPTCxMlI3KM7:TR?= Mom5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzMUe4PVcoRjJ7MUG3PFk4RC:jPh?=
AR LBD mutant MWjBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 NGTnemc1KGh? NV:4epZHUUN3MDC9JFEvOzVizszN MkfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6MUC1PFkoRjJ5OEGwOVg6RC:jPh?=
LNCAP M2XJbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFu1[mpIUTVyIE2gNk45QCEQvF2= MljvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{SxN|AoRjJ3NkO0NVMxRC:jPh?=
CWR22Rv1 NGLZUpdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkXvS2k2OCB;IEOuN|Qh|ryP M2LDclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkO0NVMxLz5{NU[zOFE{ODxxYU6=
LNCAP NUDz[XFnS3m2b4TvfIlkcXS7IHHzd4F6 MkL1O{Bl[Xm| M4\aUGdKPTBiPTC1MlEzKM7:TR?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzdzM{W2O{c,OjN5MUO1Olc9N2F-
PC3 MnXGS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkLuS2k2OCB;IEmuNVUh|ryP NIDvRW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zOFE{OCd-MkW2N|QyOzB:L3G+
CWR22Rv1 MXnD[YxtKHO3co\peoFtKGG|c3H5 NIi2dFcyPDRiaB?= NYKzdlluUUN3MDC9JFkvPyEQvF2= NX;rVod{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlE2QDZpPkK1NVIyPTh4PD;hQi=>
LNCAP MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MmLqPVYhcA>? MYDJR|UxKD1iMUGuOFch|ryP M1HrfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{CxN|Y5Lz5{N{OwNVM3QDxxYU6=
LNCaP-hr NU\qWGpmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NX;NU3k3OyCmYYnz M1jMNGlEPTBiPTCxNk42KM7:TR?= MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW4PUc,Ojd6MUC1PFk9N2F-
LNCAP MkjoRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NFLhcXg{KGSjeYO= NXXrbJE6UUN3MDC9JFEzNjVizszN MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFzN{i5O{c,OjlzMUe4PVc9N2F-
LNCaP MUPBcpRi\2:waYP0JIFkfGm4aYT5JIF{e2G7 Ml3uNVQ1KGh? Ml3HS2k2OCB;IEG4Mlg5KM7:TR?= M3\TbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkeyPFk1Lz5{OEK3Nlg6PDxxYU6=
LNCaP-AR M1Lv[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlzpNVQ1KGh? NHPHPJdIUTVyIE2gNVgvQSEQvF2= MlLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkG1PFYoRjJ3MUKxOVg3RC:jPh?=
C4-2B NIrD[oJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MV:xNkBp NHruXoZKSzVyIE2gNlAvPzdizszN MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
A31 NHnKcVZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVL3W21tPzJiaB?= NYXzT401T0l3MDC9JFI4NjVizszN NHTE[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OECxNVIyQSd-MkiwNVEzOTl:L3G+
22Rv1 NF:5fpJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MnLFPVYhcA>? M1zDZWlEPTBiPTCzNU44PiEQvF2= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzNyMUO2PEc,Ojd|MEGzOlg9N2F-
22Rv1 M2nMUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MoP4PVYhcA>? NYHj[4dVUUN3MDC9JFMyNjd4IN88US=> Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkW4OlIoRjJ4OU[1PFYzRC:jPh?=
DU145 NHXhdVdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M3rxXFk3KGh? MoXkTWM2OCB;IEOyMlI4KM7:TR?= NGTrb3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{OwNVM3QCd-MkezNFE{Pjh:L3G+
LNCAP M3W0ZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NUiwdYhQPzJiaB?= MVrJR|UxKD1iM{OuPFQh|ryP MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NEixN|koRjJ7NES4NVM6RC:jPh?=
CW22Rv1 MnzjRY51[WexbnnzeEBi[3Srdnn0fUBie3OjeR?= NV;JcGl4PzJiaB?= M3vJXWlEPTBiPTCzOU44PSEQvF2= MlmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{N{K4PVQoRjJ6MkeyPFk1RC:jPh?=
22Rv1 NX3M[|FKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MkPlO|IhcA>? NVi4OWJNUUN3MDC9JFM3NjZ4IN88US=> M4nxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NES4NVM6Lz5{OUS0PFE{QTxxYU6=
22Rv1 M4fHUmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NWrVOmhHOTJiaB?= NXq5cYR3UUN3MDC9JFM3NjZ4IN88US=> MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NUi1NVgoRjJ7N{W4OVE5RC:jPh?=
LNCAP NWDtUVZ1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NHj0RYkyOiCq M1qzNGlEPTBiPTC0Nk4{PyEQvF2= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd3OEWxPEc,Ojl5NUi1NVg9N2F-
DU145 M{jRS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MkPBN{Bl[Xm| NX34PZd3UUN3MDC9JFQ3NjFizszN MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzhzMEW4PUc,Ojd6MUC1PFk9N2F-
DU145 NXPVfXZ7SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NGHrSmk{KGSjeYO= MlzwTWM2OCB;IES2MlEh|ryP MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTFzN{i5O{c,OjlzMUe4PVc9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AR-FL / AR-v7 / pAR(S213) / pAkt(S473) / pMdm2(S166); 

PubMed: 26378044     


LNCaP95 (LN95) cells were maintained in medium containing 5% CSS and then treated with 5μM of enzalutamide (ENZ) for 0-24 hours. Whole cell lyses were extracted. AR-FL, AR-v7, phosphor-AR(ser213), phosphorAkt(ser473), total Akt, total PP-1, phosphor-Mdm2(ser166), total Mdm2 and β-actin were measured by immunoblotting.

AR / ERG / NOTCH1 / PSA / Cleaved PARP1 / Cleaved caspase 7; 

PubMed: 28607007     


Treatment of VCaP cells with NOTCH inhibitor, GSI-1, in combination with Enzalutamide (Enz) augmentes its effects on the inhibition of AR, ERG, PSA, NOTCH1 and NOTCH2 expression and induces cleavage of PARP1 and Caspase 7

CXCR7; 

PubMed: 29277895     


Western blotting is used to analyze CXCR7 protein levels in VCaP and C4-2B cells.

26378044 28607007 29277895
Growth inhibition assay
Cell proliferation; 

PubMed: 28115200     


Proliferation of the LNCaP prostate cancer cell line, the Ramos Burkitt's cell line, and the Granta, Jeko-1, Rec-1 and Maver-1 MCL cell lines plated in charcoal stripped serum for 96 hours in the absence or presence of enzalutamide (10uM). Data are representative of 3 independent experiments.

28115200
Immunofluorescence
CXCR7; 

PubMed: 29277895     


Immunofluorescence staining is used to analyze CXCR7 protein levels in prostate cancer cells.

pAKT(S473); 

PubMed: 27588408     


Representative immunofluorescent images of subcellular localization of pAKT S473 expression in PC3 cells expressing AR-V7 that were treated with vehicle control (Ctrl), enzalutamide, ISA-2011B and combination of enzalutamide and ISA-2011B (ENZ+ISA2011B). The cancer cells are indicated by the arrows.

AR; 

PubMed: 27588408     


Representative immunofluorescent images show the expression and subcellular localization of AR in 22Rv1 cells overexpressing PIP5K1α that were treated with vehicle control, enzalutamide, ISA-2011B and combination of enzalutamide and ISA-2011B.

29277895 27588408
ELISA
osteoprotegerin; 

PubMed: 27015557     


MDA-MB-231 cells were treated with 10 μM enzalutamide or vehicle for 48 hours. Levels of OPG (osteoprotegerin) in the supernatant of MDA-MB-231 cells as determined by ELISA. Data are representative of 2 independent experiments.

27015557
In vivo Enzalutamide induces great tumor regression in castrate male mice bearing LNCaP/AR xenografts at a dose of 10 mg/kg. [1]

Protocol

Kinase Assay:[3]
- Collapse

AR reporter assay:

Enzalutamide is evaluated by an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells are engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells are also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer. The antagonistic activity of Enzalutamide is tested in the presence of 100 pM of R1881. Engineered LNCaP cells are maintained in Iscove's medium containing 10% fetal bovine serum (FBS). Two days prior to Enzalutamide treatment, the cells are grown in Iscove's medium containing 10% charcoal-stripped FBS (CS-FBS) to deprive of androgens. The cells are split and grown in Iscove's medium containing 10% CS-FBS with 100 pM of R1881 and increasing concentrations of Enzalutamide. After two days of incubation, reporter activities are assayed.
Cell Research:[1]
- Collapse
  • Cell lines: LNCaP or LNCaP/AR cells
  • Concentrations: 0-10 μM
  • Incubation Time: 1-4 days
  • Method: Enzalutamide is diluted in DMSO. LNCaP or LNCaP/AR cells (104 cells/well) are androgen-starved by growth in media containing 5-10% charcoal-stripped serum for 3-5 days. Then the cells are challenged with various concentrations of Enzalutamide in media containing 5-10% charcoal-stripped serum.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Castration-resistant LNCaP/HR xenografts in male SCID mice
  • Dosages: 10 mg/kg
  • Administration: Administered via gavage daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 92 mg/mL (198.08 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.44
Formula

C21H16F4N4O2S

CAS No. 915087-33-1
Storage powder
in solvent
Synonyms N/A
Smiles CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04335682 Recruiting Drug: Darolutamide|Drug: Enzalutamide Metastatic Prostate Cancer|Prostate Cancer Metastatic|Prostate Cancer|Castrate Resistant Prostate Cancer Alliance Foundation Trials LLC.|Bayer August 17 2021 Phase 2
NCT04655365 Not yet recruiting Drug: Enzalutamide capsule Prostate Cancer CHU de Quebec-Universite Laval|Astellas Pharma Europe Ltd. January 4 2021 Phase 2
NCT04475601 Terminated Drug: Enzalutamide Pill COVID-19|Corona Virus Infection Andreas Josefsson|Umeå University|Sahlgrenska University Hospital Sweden|University Hospital Umeå|Uppsala University Hospital|Skane University Hospital|Jonkoping County Hospital|Sundsvall Hospital|Helsingborgs Hospital|Göteborg University|Astellas Pharma Europe Ltd.|Norrlands University Hospital|Västerbotten County Council July 15 2020 Phase 2
NCT04456049 Not yet recruiting Drug: Enzalutamide COVID-19 Infection Ricardo Pereira Mestre|Oncology Institute of Southern Switzerland|Institute of Oncology Research|Institute for Research in Biomedicine|Ente Ospedaliero Cantonale Bellinzona July 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Androgen Receptor Signaling Pathway Map

Androgen Receptor Inhibitors with Unique Features

Related Androgen Receptor Products

Tags: buy Enzalutamide (MDV3100) | Enzalutamide (MDV3100) supplier | purchase Enzalutamide (MDV3100) | Enzalutamide (MDV3100) cost | Enzalutamide (MDV3100) manufacturer | order Enzalutamide (MDV3100) | Enzalutamide (MDV3100) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID